This mutation is therefore predicted to be inactivating...Therefore, in the appropriate clinical context, testing for the presence of germline mutations in BRCA2 is recommended.” The report stated that the MLH1 mutation, “E694*”, “observed in this tumor results in a truncation of the 756-amino acid Mlh1 protein at amino acid 700. The gene discussed is BRCA2; the disease is neoplasm.